Using DNA Blood Tests and Software to Guide Anticoagulation in Adults with Cancer-Related Venous Thromboembolism

What this Trial Is About

Researchers are evaluating whether a software tool called the ctDNAVTE risk score model can effectively predict the chance of Venous Thromboembolism VTE returning in people who have already received blood-thinning treatment. This study focuses on adults with cancer-associated VTE, including deep venous thrombosis or pulmonary embolism, aiming to guide future anticoagulant treatment decisions. The trial is sponsored by Memorial Sloan Kettering Cancer Center and is a nonrandomized interventional study. Participants will undergo testing using MSK-ACCESS, a ctDNA sequencing assay, combined with a machine learning-based VTE risk score. Based on the model, participants are classified as either low risk 5% or less chance of VTE recurrence or high risk greater than 5% chance. This classification guides their management within the study. The study does not involve randomization or blinding and categorizes participants into two experimental arms based on their risk level. Throughout the study, participants will be monitored for the main outcome, which is the cumulative incidence of recurrent VTE over six months. The study involves regular assessments to track VTE recurrence. Participants are adults aged 18 or older with a history of cancer-related VTE who have completed anticoagulation therapy between 3 and 12 months. The total duration and detailed follow-up procedures will be according to the study protocol ending in 2030.

Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism